test Seoul biotech startups enter Boston pipeline through LabCentral
Seoul biotech startups take part in LabCentral’s The Loop program in Boston on Tuesday, seeking connections with global drugmakers and investors / Courtesy of Seoul Metropolitan Government Seoul is opening a new route into Boston’s biotech ecosystem by partnering with LabCentral, a leading startup incubator, to help three Seoul biotech companies pursue investors, pharmaceutical partners and…
Three biotech firms from Seoul are participating in LabCentral's The Loop program in Boston, aiming to forge ties with major pharmaceutical companies and investors. LabCentral, a prominent startup incubator based in Cambridge's Kendall Square, is facilitating the four-day program, which concludes on Friday. This initiative is part of The Loop, another LabCentral project that has brought together over 20 companies from 10 nations, providing them with direct access to Boston's thriving life sciences industry.
Established in 2013, LabCentral's network of early-stage biotech companies has collectively secured $21 billion in funding and generated approximately 7,800 jobs. One notable success story from this ecosystem is Affinivax, which was acquired by GSK in 2022 for a sum up to $3.3 billion.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- test Seoul rolls out 23-day welcome push for autumn tourist surge koreatimes.co.kr
